Low Levels of "Memory Protein" Linked to Cognitive Decline in Alzheimer's Disease
Working with human brain tissue samples and genetically engineered mice, Johns Hopkins Medicine researchers together with colleagues at the National Institutes of Health (NIH), the University of California San Diego Shiley-Marcos Alzheimer’s Disease Research Center, Columbia University and the Institute for Basic Research in Staten Island say that consequences of low levels of the protein NPTX2 in the brains of people with Alzheimer’s disease (AD) may change the pattern of neural activity in ways that lead to the learning and memory loss that are hallmarks of the disease. This discovery will lead to important research and may one day help experts develop new and better therapies for AD and other forms of cognitive decline. AD currently affects more than five million Americans.
Click here to read more.
Current Techniques in the Treatment of Cranial & Spinal Disorders
Oct. 21, 2017; Bromfield, Colo.
Microsurgical Approaches to Aneurysms and Skull Base Diseases 2017
Oct. 26-28, 2017; Jacksonville, Fla.
Pituitary Tumors: Diagnostic and Treatment Dilemmas
Oct. 27, 2017; New York